Pharvaris N.V.(PHVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHVS Pharvaris N.V.

Market Closed 12-12 16:00:00 EST

24.16

+0.18

+0.75%

盘后24.67

+0.51+2.12%

19:36 EST

High24.63	Low23.71	Vol367.44K
Open24.10	D1 Closing23.98	Amplitude3.82%
Mkt Cap1.57B	Tradable Cap819.16M	Total Shares64.96M
T/O8.86M	T/O Rate1.08%	Tradable Shares33.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PHVS","market":"US","secType":"STK","nameCN":"Pharvaris N.V.","latestPrice":24.16,"timestamp":1765573200000,"preClose":23.98,"halted":0,"volume":367440,"hourTrading":{"tag":"盘后","latestPrice":24.6723,"preClose":24.16,"latestTime":"19:36 EST","volume":103129,"amount":2491682.735,"timestamp":1765586172417},"delay":0,"floatShares":33905700,"shares":64959500,"eps":-3.402257,"marketStatus":"Market Closed","change":0.18,"latestTime":"12-12 16:00:00 EST","open":24.1,"high":24.625,"low":23.71,"amount":8863465.20984,"amplitude":0.038157,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.402257,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":23.98,"preHourTrading":{"tag":"盘前","latestPrice":24,"preClose":23.98,"latestTime":"04:53 EST","volume":64,"amount":1529.229952,"timestamp":1765533214354},"postHourTrading":{"tag":"盘后","latestPrice":24.6723,"preClose":24.16,"latestTime":"19:36 EST","volume":103129,"amount":2491682.735,"timestamp":1765586172417},"volumeRatio":0.9952825128746203,"impliedVol":0.4685,"impliedVolPercentile":0.1714},"requestUrl":"/m/hq/s/PHVS","defaultTab":"news","newsList":[{"id":"2589582106","title":"Pharvaris (PHVS): Reassessing Valuation After Strong RAPIDe-3 Phase 3 Success in Hereditary Angioedema","url":"https://stock-news.laohu8.com/highlight/detail?id=2589582106","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589582106?lang=en_us&edition=fundamental","pubTime":"2025-12-07 02:14","pubTimestamp":1765044857,"startTime":"0","endTime":"0","summary":"Pharvaris (NasdaqGS:PHVS) just cleared a major clinical hurdle, with its RAPIDe-3 Phase 3 trial of oral deucrictibant hitting all primary and secondary endpoints in hereditary angioedema. The company intends to use these data as the basis for 2026 approval filings.\nSee our latest analysis for Pharvaris.\nEven with the recent pullback, including a 1 day share price return of minus 4.6 percent and minus 6.9 percent over 7 days, Pharvaris still shows building momentum with a 30 day share price...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/pharvaris-phvs-reassessing-valuation-after-strong-rapide-3-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/pharvaris-phvs-reassessing-valuation-after-strong-rapide-3-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","PHVS","BK4007"],"gpt_icon":0},{"id":"2589835185","title":"Pharvaris' Phase 3 Trial of Deucrictibant for HAE Attacks Confirms a Differentiated On-Demand Profile, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2589835185","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589835185?lang=en_us&edition=fundamental","pubTime":"2025-12-05 00:00","pubTimestamp":1764864034,"startTime":"0","endTime":"0","summary":"Pharvaris'  phase 3 trial of deucrictibant for hereditary angioedema attacks meeting primary and secondary endpoints confirms a differentiated oral on-demand profile, Morgan Stanley said in a Wednesday note.The company remains on track for new drug application submission to the US Food and Drug Administration in H1 2026, with the prophylactic data readout from the ongoing chapter-3 phase 3 study expected in H2 2026, according to the note.The firm said that the prophylactic opportunity is larger than on-demand, with Pharvaris guiding to 67% of the population at present, growing to around 80% in terms of value in the prophylactic space.The firm said it modeled a 65% probability of success for the prophylactic candidate and a 90% probability of success for the on-demand candidate.Morgan Stanley raised the company's price target to $41 from $37, with an overweight rating.Price: 28.16, Change: -1.21, Percent Change: -4.10","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0106261612.USD","LU2271345857.HKD","IE00BKVL7J92.USD","LU0106831901.USD","LU1791710400.SGD","LU1720051017.SGD","LU0205194284.USD","LU0795875169.SGD","LU0882574139.USD","IE00B19Z6F94.USD","LU1989772840.SGD","LU0098860793.USD","LU0234570918.USD","BK4585","LU1548497426.USD","LU0971096721.USD","LU0557290698.USD","IE0034390439.USD","LU1169590202.USD","LU0158827781.USD","LU2023251221.USD","LU2347655156.SGD","IE00BZ1G4Q59.USD","HAE","LU2089284900.SGD","LU2089283258.USD","LU1732799900.SGD","BK4504","LU1244550494.USD","PHVS","LU0225283273.USD","LU0528227936.USD","LU1244550221.USD","LU2028103732.USD","BK4007","LU2357305700.SGD","LU1244550577.SGD","LU1791710582.SGD","LU1074936037.SGD","LU0320765646.SGD","LU0106261372.USD","LU0267386448.USD","IE00B64QTZ34.USD","LU0006306889.USD","LU1989772923.USD","BK4198","LU1732800096.USD","BK4588","MS","LU1363072403.SGD"],"gpt_icon":0},{"id":"2588882499","title":"Pharvaris Nv : Oppenheimer Raises Target Price to $50 From $44","url":"https://stock-news.laohu8.com/highlight/detail?id=2588882499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588882499?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:31","pubTimestamp":1764855073,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2588088236","title":"Pharvaris Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2588088236","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588088236?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:14","pubTimestamp":1764854040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2025 08:14 ET (13:14 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2588881553","title":"Pharvaris Is Maintained at Neutral by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881553","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881553?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:23","pubTimestamp":1764850980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2025 07:23 ET (12:23 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2588889711","title":"Morgan Stanley Raises Price Target on Pharvaris to $41 From $37, Keeps Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2588889711","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588889711?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:18","pubTimestamp":1764850684,"startTime":"0","endTime":"0","summary":"Pharvaris (PHVS) has an average rating of buy and mean price target of $46.03, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2588026290","title":"Pharvaris Price Target Maintained With a $60.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588026290","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588026290?lang=en_us&edition=fundamental","pubTime":"2025-12-04 03:23","pubTimestamp":1764789780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 14:23 ET (19:23 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2588502650","title":"BUZZ-U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox","url":"https://stock-news.laohu8.com/highlight/detail?id=2588502650","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588502650?lang=en_us&edition=fundamental","pubTime":"2025-12-04 02:53","pubTimestamp":1764788004,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, RobloxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL6N3X90ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBU","CNX","EQT","THO","SCCO","NUVB","CHCO","CXM","AEO","KMTS","DAKT","PSTG","PHVS","CASY","LU0689626769.HKD","FCX","GTLB","MCHP","AU","DLTR","BA","CVX","BDTX","TRGP","RBLX","CAPR","NEXT","CBSH","NXT","IXHL","MRBK","EQIX","APA","FNB","WEN","ARE","STRK","XOM","SPR","BMY","OKTA"],"gpt_icon":1},{"id":"2588040270","title":"BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics","url":"https://stock-news.laohu8.com/highlight/detail?id=2588040270","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588040270?lang=en_us&edition=fundamental","pubTime":"2025-12-03 23:57","pubTimestamp":1764777433,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, DaktronicsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Cal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL6N3X90XO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEO","LU0300736062.USD","SCCO","MRBK","ARE","OKTA","BDTX","CVX","GTLB","DLTR","APA","CHCO","GB00B4LPDJ14.GBP","DAKT","CAPR","STRK","THO","BMY","LU0689472784.USD","NUVB","SG9999018857.SGD","IXHL","LU0314104364.USD","LU1712237335.SGD","NXT","SG9999014880.SGD","LU0266512127.USD","CXM","PHVS","LU2602419157.SGD","AU","WEN","MSFT","FCX","XOM","CBU","EQIX","MCHP","PSTG","TRGP","FNB","CASY","KMTS"],"gpt_icon":1},{"id":"2588404708","title":"Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2588404708","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588404708?lang=en_us&edition=fundamental","pubTime":"2025-12-03 23:09","pubTimestamp":1764774540,"startTime":"0","endTime":"0","summary":"Pharvaris reports Phase 3 data showing its oral HAE treatment delivers rapid relief, fewer second doses and strong safety results.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/03/Medical-Concept-Meaning-Angioedema-With-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/03/Medical-Concept-Meaning-Angioedema-With-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49185642/pharvaris-pill-provides-rapid-relief-in-patients-with-rare-swelling-attacks-data-shows","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49185642/pharvaris-pill-provides-rapid-relief-in-patients-with-rare-swelling-attacks-data-shows","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","BK4588","LU1978683503.SGD","LU0106261612.USD","SG9999001440.SGD","IR","LU1169589451.USD","LU0012050646.USD","LU0256863811.USD","LU0205194284.USD","IE0034390439.USD","LU0205193047.USD","KALV","IE00B64QTZ34.USD","LU0256863902.USD","HAE","IE00BLDYK493.USD","LU0417517546.SGD","IONS","BK4585","IE00B19Z6F94.USD","BK4161","PHVS","LU1169590202.USD","BK4139","BK4198","LU0124384867.USD"],"gpt_icon":0},{"id":"2588042989","title":"Pharvaris Shares Gain 1.2% After Phase 3 Trial Results for Its Hereditary Angioedema Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2588042989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588042989?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:34","pubTimestamp":1764772464,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL4N3X916M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2588304426","title":"Sector Update: Health Care Stocks Advance Premarket Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2588304426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588304426?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:17","pubTimestamp":1764771437,"startTime":"0","endTime":"0","summary":"Health care stocks were advancing premarket Wednesday, with the iShares Biotechnology ETF  0.4% higher and the Health Care Select Sector SPDR Fund  up 0.2%.Bristol-Myers Squibb  shares were up more than 2% after the company said it will enroll additional participants in a late-stage trial that is evaluating the safety and efficacy of Cobenfy to treat psychosis associated with Alzheimer's disease dementia.Pharvaris  stock was up more than 7% after the company said a global phase 3 study of its investigational therapy deucrictibant met the primary endpoint of rapid symptom relief as well as all secondary efficacy endpoints in patients suffering acute hereditary angioedema attacks.Capricor Therapeutics  shares were up more than 14% after the company said a pivotal late-stage trial evaluating its investigational cell therapy Deramiocel to treat boys and young men with Duchenne muscular dystrophy met both its primary endpoint and a key secondary endpoint.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B2B36J28.USD","IE00BJT1NW94.SGD","XLV","LU0237698245.USD","LU0114720955.EUR","LU1032466523.USD","LU1868837300.USD","IBB","BK4559","LU0882574055.USD","LU0225771236.USD","LU1670710588.SGD","LU0456855351.SGD","LU1868836914.USD","IE00BFXG1179.USD","BMY","IE0009355771.USD","BK4585","LU1868836591.USD","LU1093756325.SGD","BK4139","LU1868836757.USD","LU2242652126.USD","BK4007","LU0306806265.USD","BK4581","BK4532","LU0061475181.USD","BK4588","LU1670710661.SGD","LU1718418525.SGD","LU1093756168.USD","PHVS","LU1323610961.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4534","LU1571399168.USD","LU1430594728.SGD","LU2125154778.USD","LU2242646821.SGD","LU1868837136.USD","LABU","LU1670711123.USD","CAPR","LU2133065610.SGD","LU2360032135.SGD","LU1585245621.USD","IE0002141913.USD","XBI"],"gpt_icon":0},{"id":"2588418720","title":"BUZZ-Pharvaris jumps as oral therapy for genetic disorder meets main goal in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588418720","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588418720?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:33","pubTimestamp":1764768804,"startTime":"0","endTime":"0","summary":"BUZZ-Pharvaris jumps as oral therapy for genetic disorder meets main goal in late-stage trial** Shares of oral therapy developer Pharvaris PHVS.O rise 11.9% to $27 premarket** Co's oral therapy, Deucr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL6N3X90SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2588046762","title":"Pharvaris Shares Jump 19.6% Premarket After Phase 3 Trial Results for Its Hereditary Angioedema Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046762?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:01","pubTimestamp":1764766893,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL4N3X90ZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2588046198","title":"BRIEF-Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046198","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046198?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:57","pubTimestamp":1764766633,"startTime":"0","endTime":"0","summary":"BRIEF-Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study Dec 3 (Reuters) - Pharvaris NV PHVS.O:PHARVARIS ANNOUNCES POSITIVE TOPLINE DATA FROM RAPIDE-3 PIVOTAL STUDY CONFIRMING POTEN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUAHCGK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2588045953","title":"Pharvaris Meets Endpoints in Study of Hereditary Angioedema Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045953","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588045953?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:19","pubTimestamp":1764764340,"startTime":"0","endTime":"0","summary":"Pharvaris's phase three study of its deucrictibant treatment for hereditary angioedema met its primary endpoint and all secondary efficacy endpoints.The company said median time to onset of symptom relief, its primary endpoint, was 1.28 hours, significantly faster than the placebo. It also met secondary efficacy endpoints, including time to end of progression and complete symptom resolution.The study confirmed the well-tolerated safety profile of the treatment, the company said.The data from the study will serve as the basis for market authorization applications which Pharvaris plans to file beginning in the first half of 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","BK4007"],"gpt_icon":0},{"id":"2588043685","title":"Pharvaris Announces Positive Phase 3 Results for Deucrictibant in On-Demand HAE Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2588043685","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588043685?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:50","pubTimestamp":1764762613,"startTime":"0","endTime":"0","summary":"Pharvaris NV has announced positive topline results from its RAPIDe-3 pivotal Phase 3 study evaluating the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema  attacks. The study met its primary endpoint, with a median time to onset of symptom relief achieved in 1.28 hours, significantly faster than placebo . All secondary efficacy endpoints were also met, including median times to End of Progression  and complete symptom resolution . Deucrictibant demonstrated a well-tolerated safety profile, and efficacy and safety outcomes were consistent across all HAE subtypes and attack severities. The results were presented during a live conference call and webcast hosted by Pharvaris, with an archived replay available on the company's investor relations website. The data will serve as the basis for marketing authorization applications planned for submission starting in the first half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL8BmGwJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","PHVS","IE00BGHQF748.EUR","LU2210149790.SGD","LU2095319765.USD","BK4585","IE00BKPKM429.USD","BK4112","BK4588","IE00B64PRP62.GBP","NDAQ"],"gpt_icon":0},{"id":"2588571043","title":"Pharvaris Nv - Deucrictibant Confirmed to Have Well-Tolerated Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2588571043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588571043?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:50","pubTimestamp":1764762600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUAHCGK8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2588435760","title":"Pharvaris Nv - to Submit Nda to FDA in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588435760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588435760?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:50","pubTimestamp":1764762600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUAHCGK8:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHVS"],"gpt_icon":0},{"id":"2588043579","title":"Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study Confirming Potential of Deucrictibant for on-Demand Treatment of Hae Attacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2588043579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588043579?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:50","pubTimestamp":1764762600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUAHCGK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHVS","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pharvaris.com","stockEarnings":[{"period":"1week","weight":-0.0855},{"period":"1month","weight":-0.0639},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.4467},{"period":"1year","weight":0.2702},{"period":"ytd","weight":0.2603}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.005341},{"month":2,"riseRate":0,"avgChangeRate":-0.10879},{"month":3,"riseRate":0.4,"avgChangeRate":-0.042615},{"month":4,"riseRate":0.6,"avgChangeRate":0.04111},{"month":5,"riseRate":0.2,"avgChangeRate":-0.101468},{"month":6,"riseRate":0.6,"avgChangeRate":0.189847},{"month":7,"riseRate":0.4,"avgChangeRate":0.02128},{"month":8,"riseRate":0.8,"avgChangeRate":-0.020522},{"month":9,"riseRate":0.6,"avgChangeRate":-0.015739},{"month":10,"riseRate":0.2,"avgChangeRate":-0.072433},{"month":11,"riseRate":0.4,"avgChangeRate":-0.106545},{"month":12,"riseRate":0.4,"avgChangeRate":0.933302}],"exchange":"NASDAQ","name":"Pharvaris N.V.","nameEN":"Pharvaris N.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharvaris N.V.(PHVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharvaris N.V.(PHVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharvaris N.V.,PHVS,Pharvaris N.V.股票,Pharvaris N.V.股票老虎,Pharvaris N.V.股票老虎国际,Pharvaris N.V.行情,Pharvaris N.V.股票行情,Pharvaris N.V.股价,Pharvaris N.V.股市,Pharvaris N.V.股票价格,Pharvaris N.V.股票交易,Pharvaris N.V.股票购买,Pharvaris N.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharvaris N.V.(PHVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharvaris N.V.(PHVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction